TABLE 3.
Adverse events during the LT‐ACTH period
| Daily injection period | |
|---|---|
| Irritability | 15/20 |
| Weight gain | 15/20 |
| Hypertension | 2/20 |
| Electrolyte imbalance | 6/20 |
| Urinary sugar | 1/20 |
| Infection | 1/20 |
| Gastrointestinal hemorrhage | 0/19 |
| Brain shrinkage | 10/18 |
| Others | |
| Hypertonia oculi | 1 |
| Transaminase elevation | 1 |
| Hypothyroidism | 1 |
| Chromatosis | 1 |
| Weekly injection period | |
|---|---|
| Infection | 1/21 |
| Hypertension | 2/18 |
| Cardiac hypertrophy | 0/12 |
| Gastrointestinal hemorrhage | 0/18 |
| Electrolyte imbalance | 0/19 |
| Hypertonia oculi | 0/10 |
| Cataract | 0/12 |
| Fracture | 0/19 |
| Skin trouble | 1/20 |
| Brain shrinkage | 5/10 |
| Subdural effusion/subdural hematoma | 0/12 |
| Obesity | 0/20 |
| Height stagnation | 4/15 |
| Depression | 0/21 |
| Irritability | 2/21 |
Patients who lacked information whether they had experienced each event or not were excluded from the number of corresponding denominators. Events classified as “Others” were obtained by free description in the questionnaire.
Abbreviations: LT‐ACTH, long‐term ACTH therapy.